


# T-cell receptor engineering of NK-cells to therapeutically target tumours and tumour immune evasion.

Laura T. Morton\*<sup>1</sup>, Anne K. Wouters<sup>1</sup>, Tassilo Wachsmann<sup>1</sup>, Miranda H. Meeuwsen<sup>1</sup>, Dennis F. G. Remst<sup>1</sup>, Marleen M. van Loenen<sup>2</sup>, J. H. Frederik Falkenburg<sup>1</sup> and Mirjam H.M. Heemskerk<sup>1\*</sup>

<sup>1</sup>Department of Hematology, Leiden university medical centre (LUMC), Leiden, The Netherlands


<sup>2</sup> Gadeta B.V, Utrecht, The Netherlands

## **Supplemental data**




**Supplemental figure S1 Transduction efficiencies of NK-cells.**

NK-cells were retrovirally transduced to express the murinised BOB1-TCR following a 2-step transduction protocol. 1<sup>st</sup> step was transduction with TCR-CD8 A) TCR-CD8 transduction efficiencies analysed on Day 7 by FACS for expression of CD8 $\beta$ . 2<sup>nd</sup> transduction was with the 4 invariant chains of CD3 $\epsilon\delta\gamma\zeta$  signaling complex B) CD3 transduction efficiencies analyzed on Day 14 by FACS for expression of mTCR $\beta$ . Each symbol represents an individual donor and error bars depict mean and SD.




**Supplemental figure S2 Expansion kinetics of NK:BOB1 cell products.**

NK-cells were transduced on Day 3 with TCR-CD8 gene constructs encoding the BOB1-specific TCR. At each time point cell number was determined by counting total viable cells present in culture. Each symbol represents a NK:BOB1 cell product from different donors and the solid line represents the mean expansion.




**Supplemental figure S3 Expression of CMV-specific TCR in NK-cells following two-step transduction protocol.**

NK-cells were transduced on Day 3 with TCR-CD8 encoding the HLA-A\*02:01 restricted, CMV-specific TCR and with the 4 invariant chains of CD3 on Day 9. A) Transduction efficiencies of the 1<sup>st</sup> TCR-CD8 transduction and the 2<sup>nd</sup> CD3 transduction. B) Representative histograms of CD8β, mTCRβ, CD3ε and human TCRαβ expression in a final NK-TCR cell product expressing CMV-specific TCR (NK:CMV) on Day 21. Representative FACS plot of NK:CMV stained for mTCRβ and human(hu) TCRαβ (T-cells) expression. C) Representative FACS plot of NK:CMV stained with CMV-specific or an irrelevant pMHC tetramer on day 21 post isolation. D) Summary of expression frequencies of CD8β, mTCRβ, CD3ε, huTCRαβ expression and CMV-specific tetramer binding frequencies on Day 21 of NK:CMV cell products. Symbols represent a different donor and error bars depict mean and standard deviation.




### Supplemental figure S4 Expression of PRAME-specific TCR on NK-cells permits PRAME-specific cytotoxic responses.

NK-cells derived from donor 3 were transduced to express PRAME-specific TCR targeting preferentially-expressed-antigen in melanoma (PRAME) restricted to peptide SLLQHLIGL presented in HLA-A\*02:01 (NK:PRAME). A) Transduction and enrichment efficiencies and of PRAME-CD8 and B) CD3 viral constructs measured by FACS by CD8 $\beta$  expression or CD3 $\epsilon$  expression respectively on total NK-cells. C) Histograms of CD8 $\beta$ , murine TCR $\beta$  (mTCR $\beta$ ) and CD3 $\epsilon$  expression on NK:PRAME final cell product. D) Dotplot of human TCR $\alpha\beta$  (T-cells) versus mTCR $\beta$  (transduced) expression on NK:PRAME final cell product. E) FACS analysis for PRAME-specific/Irrelevant tetramer binding of NK:PRAME. F) Cytotoxicity data of NK:PRAME and MOCK transduced NK cells against K562 (NK sensitive) and low PRAME-expressing target cell lines. HLA-A\*02:01+ cell lines were loaded with 1 $\mu$ M SLLQHLIGL peptide. Error bars represent mean and SD of technical triplicates




### Supplemental figure S5 Phenotype of NK-TCR cell products on Day 21.

NK-cells were transduced to express the BOB1-specific TCR (NK:BOB1) and in parallel NK-cells not expressing TCR (NK:TCRneg) were similarly expanded without transduction. On day 21, without further stimulation, NK-cells were harvested from culture and stained with monoclonal antibodies targeting NK activation and inhibitory receptors and co-stimulation molecules and subsequently analysed by FACS. NK-cells were 1<sup>st</sup> gated on CD56 expression and positive gates were determined using PBMCs. Each symbol represents a different donor and error bars depict mean and SD. Statistical test used was unpaired T-test.



### Supplemental figure S6 Antigen-specific cytotoxicity of NK:CMV cell products.


NK-cells were transduced to express the HLA-A\*02:01 restricted CMV-specific TCR (NK:CMV). Cytotoxicity data of NK:CMV, NK:BOB1(as a control), CMV-specific T-cell clone and BOB-specific T-cell clone against K562 (NK sensitive), HLA-A\*02:01- EBV-LCL and HLA-A\*02:01 + EBV-LCL cell lines were loaded with 1 $\mu$ M NLVPMVATV CMV-derived peptide. Error bars represent mean and SD of technical triplicates



**Supplemental figure S7 NK:BOB1 demonstrates increased antigen-specific cytotoxicity compared to CD8 T-cells expressing BOB1-TCR.**


CD8 T-cells, without endogenous TCR $\alpha\beta$  Knock out, and NK cells were isolated from the same healthy donor and transduced to express BOB1-specific TCR (CD8T:BOB1 and NK:BOB1). As negative control TCR negative NK-cells (NK:TCRneg) or CMV-specific TCR transduced CD8 T-cells (T-MOCK) were used. A) FACS analysis depicting human TCR (huTCR) expression (endogenous TCR) and murine TCR (mTCR) expression (tgTCR) from donor 1 and 2. B) Geometric Mean of mTCR expression in NK:BOB1 and CD8T:BOB1. Error bars represent SD. C) Representative data from donor 2 of BOB1-specific NK and CD8 T cell cytotoxicity at multiple effector:target (E:T) ratios. Error bars represent mean and standard error of technical triplicates. D) Combined Cytotoxicity data at 5:1 E:T ratio by NK and CD8 T cells derived from donor 1 and donor 2. E) % TCR-dependent killing calculated as the difference in killing at 5:1 E:T ratio between BOB1-TCR and negative controls. Combined data acquired from donor 1 and donor 2. *POU2AF1* encodes the BOB1 protein and expression was predetermined by qPCR. Statistical test used was unpaired T-test corrected for multiple comparisons using the Holm-Sidak method.






**Supplemental figure S8 NK:CMV and CD8T:CMV cytotoxicity against exogenously loaded antigen.**

CD8 T-cells and NK cells were isolated from the same healthy donor and transduced to express HLA-A\*02:01 restricted, CMV-specific TCR (NK:CMV) and (CD8T:CMV). For CD8T:CMV, donor 1 expressed its endogenous TCR $\alpha\beta$  (NO KO) whereas donor 2 had been CRISPR/Cas9 edited to remove endogenous TCR $\alpha\beta$  expression (ACBC KO). HLA-A\*02:01+ EBV-LCL was exogenously loaded with NLVPMVATV CMV-derived peptide at different concentrations and subsequently co-cultured with effector cells at a 10:1 E:T ratio for 6 hours Cr release assay.



**Supplemental figure S9 PMA/Ionomycin stimulation elicits cytokine production and degranulation from cell products.**

CD8T expressing BOB1-TCR or CMV-TCR (D10 post stimulation) and NK-cells expressing BOB1-TCR or TCR negative NK-cells (Day 7 post stimulation) were stimulated overnight with PMA/Ionomycin in the presence of Brefeldin-A and anti-CD107a. After 12-14 hours incubation, cells were stained for inflammatory cytokines TNFα and IFN-γ and assessed by FACS. Depicted is the combined data of cell products derived from different donors for A) CD107a, B) TNFα and C) IFN-γ expression. Live NK-cells were previously gated on CD56 expression and Live CD8T were gated on CD8 expression. Positive cells were gated according to unstimulated. Each symbol represents a different donor and error bars represent mean and SD of biological replicates. Statistical test used was unpaired T-test.



**Supplemental figure S10 NK:CMV induces antigen-specific cytokine production and degranulation from cell products.**

CD8T expressing HLA-A\*02:01 restricted CMV-TCR (D10 post stimulation) and NK-cells expressing CMV-TCR (Day 7 post stimulation) were stimulated overnight with HLA-A\*02:01+ EBV-LCL in the presence of Brefeldin-A and anti-CD107a. EBV-LCL was loaded with and without 1μM NLVPMVATV CMV-derived peptide. After 12-14 hours incubation, cells were stained for inflammatory cytokines TNFα and IFN-γ and assessed by FACS. Depicted is the combined data of cell products derived from different donors for A) CD107a, B) TNFα and C) IFN-γ expression. Live NK-cells were previously gated on CD56 expression and Live CD8T were gated on CD8 expression. Positive cells were gated according to unstimulated. Each symbol represents a different donor and error bars represent mean and SD of biological replicates..